Microbix and Copan Italia Execute Strategic Agreement

Ontario Industry Updates
Written By Maura Campbell
Micobix.png

Microbix Biosystems Inc., a life sciences innovator and exporter, and Copan Italia S.p.A., the global leader in specimen collection technologies, announced their execution of a strategic agreement in relation to Microbix’s quality assessment products (QAPs™) and Copan’s flocked devices (FLOQ®). Twelve such FLOQ-based QAPs SKUs have already been created and introduced. Of those, fully IVD-regulated REDxFLOQ controls are now available to support lab-based molecular-test workflows for the SARS-CoV-2 virus (the cause of COVID-19 disease).

Maura Campbell
Previous

Vasomune Therapeutics Announces Initiation of the First-in-Human Clinical Trial of a Potential Vascular Normalization COVID-19 Treatment
Next

MCI Onehealth Closes $30 Million Initial Public Offering